Anti-angiogenic therapy subsequent to adeno-associated-virus-mediated immunotherapy eradicates lymphomas that disseminate to the liver

International Journal of Cancer

Volumn 113, Issue 4, 2005, Pages 670-677

  Sun, Xueying ^a,b,c   Krissansen, Geoffrey W ^a   Fung, Peter W C ^b   Xu, Sue ^b   Shi, Juan ^b   Man, Kwan ^b   Fan, Sheung Tat ^b   Xu, Ruian ^b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c SHANDONG UNIVERSITY   (China)

Author keywords

Adeno associated virus; Angiostatin; B7.1; Gene therapy; Immunotherapy; Liver cancer

Indexed keywords

ADENOVIRUS VECTOR; ANGIOSTATIN;

ADENO ASSOCIATED VIRUS; ANIMAL CELL; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; IMMUNOTHERAPY; LIVER CANCER; LIVER METASTASIS; LYMPHOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; SURVIVAL RATE; T LYMPHOCYTE; TUMOR CELL; VACCINATION;

ANGIOGENESIS INHIBITORS; ANGIOSTATINS; ANIMALS; ANTIGENS, CD80; DEPENDOVIRUS; IMMUNOTHERAPY; LIVER NEOPLASMS; LYMPHOMA; MALE; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; SPLEEN; SURVIVAL RATE; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; VACCINATION;

EID: 11144316756     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20624     Document Type: Article

References (30)

1. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994;79:185-8.
2. Takayama T, Sekine T, Makuuchi M, Yamasaki, S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000;356:802-7.
3. Baskar S, Ostrand-Rosenberg S, Nabavi N, Nadler LM, Freeman GJ, Glimcher LH. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc Natl Acad Sci USA 1993;90:5687-90.
4. Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, McGowan P, Linsley PS. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992;71:1093-102.
5. Townsend SE, Allison JP. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 1993;259:368-70.
6. Kanwar JR, Berg RW, Lehnert K, Krissansen GW. Taking lessons from dendritic cells: multiple xenogeneic ligands for leukocyte integrins have the potential to stimulate anti-tumor immunity. Gene Ther 1999;6:1835-44.
7. Sun X, Kanwar JR, Leung E, Lehnert K, Wang D, Krissansen GW. Angiostatin enhances B7.1-mediated cancer immunotherapy independently of effects on vascular endothelial growth factor expression. Cancer Gene Ther 2001;8:719-27.
8. Sun X, Leung E, Kanwar JR, Lehnert K, Wang D, Krissansen GW. Gene transfer of antisense hypoxia inducible factor-1α enhances the therapeutic efficacy of cancer immunotherapy. Gene Ther 2001;8:638-45.
9. Kim K-R, Moon H-E, Kim K-W. Hypoxia-induced angiogenesis in human hepatocellular carcinoma. J Mol Med 2002;80:703-14.
10. Lovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-17.
11. Xu R, Sun X, Chan D, Tse L-Y, Xu S, Xiao W, Kung H-F, Krissansen GW, Fan S-T. Long-term expression of angiostatin suppresses liver metastatic cancer in mice. Hepatology 2003;47:1451-60.
12. Xu L, Daly T, Gao C, Flotte TR, Song S, Byrne BJ, Sands MS, Parker PK. CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice. Hum Gene Ther 2001;12:563-7.
13. Donello J, Loeb JE, Hope TJ. Woodchuck hepatitis virus contains a tripartite posttranscriptional regulatory element. J Virol 1998;72:5085-92.
14. Xu R, Janson CG, Mastakov M, Lawlor P, Young D, Mouravlev A, Fitzsimons H, Choi KL, Ma H, Dragunow M, Leone P, Chen Q, et al. Quantitative comparison of expression with adeno-associated virus (AAV-2) brain-specific gene cassettes. Gene Ther 2001;8:1323-32.
15. Xiao W, Chirmule N, Schnell MA, Tazelaar J, Hughes JV, Wilson JM. Route of administration determines induction of T cell independent humoral response to adeno-associated virus vectors. Mol Ther 2000;1:323-9.
16. Liu Y, Chiriva-Internati M, Grizzi F, Salati E, Roman JJ, Lim S, Hermonat PL. Rapid induction of cytotoxic T-cell response against cervical cancer cells by human papillomavirus type 16 E6 antigen gene delivery into human dendritic cells by an adeno-associated virus vector. Cancer Gene Ther 2001;8:948-57.
17. Tada H, Maron DJ, Choi EA, Barsoum J, Lei H, Xie Q, Liu W, Ellis L, Moscioni AD, Tazelaar J, Fawell S, Qin X, et al. Systemic IFN-β gene therapy results in long-term survival in mice with established colorectal liver metastases. J Clin Invest 2001;108:83-95.
18. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29:15-8.
19. Bouquet C, Frau E, Opolon P, Connault E, Abitobl M, Griscelli F, Yeh P, Perricaudet M. Systemic administration of a recombinant adenovirus encoding a HAS-angiostatin Kringle 1-3 conjugate inhibits MDA-MB-231 tumor growth and metastasis in a transgenic model of spontaneous eye cancer. Molec Therapy J Am Soc Gene Therapy 2003;7:174-84.
20. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumours in mice. Nat Med 1996;2:689-92.
21. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-28.
22. Pawliuk R, Bachelot T, Zurkiya O, Eriksson A, Cao Y, Leboulch P. Continuous intravascular secretion of endostatin in mice from transduced hematopoietic stem cells. Molec Therapy J Am Soc Gene Therapy 2002;5:345-51.
23. Eisterer W, Jiang X, Bachelot T, Pawliuk R, Abramovich C, Leboulch P, Hogge D, Eaves C. Unfulfilled promise of endostatin in a gene therapy-xenotransplant model of human acute lymphocytic leukemia. Molec Therapy J Am Soc Gene Therapy 2002;5:352-9.
24. Ostrand-Rosenberg S, Baskar S, Patterson N, Clements VK. Expression of MHC class II and B7-1 and B7-2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells. Tissue Antigens 1996;47:414-21.
25. Pulaski BA, Term DS, Khan S, Muller E, Ostrand-Rosenberg S. Cooperativity of Straphylococcal aureus enterotoxin B superantigen, Major Histocompatibility Complex Class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model. Cancer Res 2000;60:2710-5.
26. Kanwar JR, Shen WP, Berg R, Krissansen GW. Effect of survivin antagonists on the growth of established tumors and B7.1 immunogene therapy. J Natl Cancer Inst 2001;93:1541-52.
27. Mauceri HJ, Seetharam S, Beckett MA, Schumm LP, Koons A, Gupta VK, Park JO, Manan A, Lee JY, Montag AG, Kufe DW, Weichselbaum RR. Angiostatin potentiates cyclophosphamide treatment of metastatic disease. Cancer Chemother Pharmacol 2002;50:412-8.
28. Bass C, Cabrera G, Elgavish A, Robert B, Siegal GP, Anderson SC, Maneval DC, Curiel DT. Recombinant adenovirus-mediated gene transfer to genitourinary epithelium in vitro and in vivo. Cancer Gene Ther 1995;2:97-104.
29. de Roos WK, Fallaux FJ, Marinelli AW, Lazaris-Karatzas A, von Geusau AB, van der Eb MM, Cramer SJ, Terpstra OT, Hoeben RC. Isolated-organ perfusion for local gene delivery: efficient adenovirus-mediated gene transfer into the liver. Gene Ther 1997;4:55-62.
30. Lee SS, Einsenlohr LC, McCue PA, Mastrangelo MJ, Lattime EC. Intravesical gene therapy: in vivo gene transfer using recombinant vaccine virus vectors. Cancer Res 1994;54:3325-8.